Clinical Trial: Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Substance-Related Disorders
Study Type: INTERVENTIONAL
Official Title: Phase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Brief Summary:
This is a randomized, double-blind, placebo-controlled phase 2b pilot clinical trial to determine whether non-ergoline D3/D2/D1 dopamine (DA) receptor agonist rotigotine (RTG), in combination with treatment as usual, including individual or group behavioral therapy can a) reduce cocaine use and also b) increase brain activity in frontocortical areas of the brain, and, as a reflection of that - improve top-down cognitive control in persons with cocaine use disorder (CocUD).Rotigotine is a marketed non-ergoline…
Read more